Advanced

Oral iodinated activated charcoal improves lung function in patients with COPD.

Skogvall, Staffan; Erjefält, Jonas LU ; Olin, Anders LU ; Ankerst, Jaro LU and Bjermer, Leif LU (2014) In Respiratory Medicine 108(6). p.905-909
Abstract
The effect of 8 weeks treatment with oral iodinated activated charcoal (IAC) on lung function of patients with moderate chronic obstructive pulmonary disease (COPD) was examined in a double blind randomized placebo controlled parallel group study with 40 patients. In the IAC group, patients showed a statistically significant improvement of FEV1 baseline by 130 ml compared to placebo, corresponding to 8.2% improvement (p = 0.031*). Correlation statistics revealed that the improvement of FEV1 baseline was significantly correlated both to FEV1 post-bronchodilator (p = 0.0020**) and FEV1 post-exercise (0.033*) values. This demonstrates that the improved baseline lung function by IAC did not inhibit a further beta2-adrenoceptor relaxation, and... (More)
The effect of 8 weeks treatment with oral iodinated activated charcoal (IAC) on lung function of patients with moderate chronic obstructive pulmonary disease (COPD) was examined in a double blind randomized placebo controlled parallel group study with 40 patients. In the IAC group, patients showed a statistically significant improvement of FEV1 baseline by 130 ml compared to placebo, corresponding to 8.2% improvement (p = 0.031*). Correlation statistics revealed that the improvement of FEV1 baseline was significantly correlated both to FEV1 post-bronchodilator (p = 0.0020**) and FEV1 post-exercise (0.033*) values. This demonstrates that the improved baseline lung function by IAC did not inhibit a further beta2-adrenoceptor relaxation, and thus that patients did not reach a limit for maximal improvement of the lung function after IAC treatment. Eight patients in the IAC group developed abnormal thyroid hormone levels transiently during the treatment. This side effect was not correlated to improvement of lung function (p = 0.82). No serious adverse effects directly related to the treatment were recorded. In summary, this study demonstrates that iodinated activated charcoal surprisingly and significantly improved lung function of patients with moderate COPD. The underlying mechanism of action is unclear, but is likely to be different from the drugs used today. The immediate conclusion is that further studies are now justified in order to determine clinical efficacy of IAC in COPD and explore possible mechanisms of action. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Respiratory Medicine
volume
108
issue
6
pages
905 - 909
publisher
Elsevier
external identifiers
  • pmid:24742364
  • wos:000338409500011
  • scopus:84902294264
ISSN
1532-3064
DOI
10.1016/j.rmed.2014.03.001
language
English
LU publication?
yes
id
d9767e6d-ed00-4a38-ba68-27781106c77e (old id 4429924)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24742364?dopt=Abstract
date added to LUP
2014-05-05 17:45:06
date last changed
2017-01-01 03:22:56
@article{d9767e6d-ed00-4a38-ba68-27781106c77e,
  abstract     = {The effect of 8 weeks treatment with oral iodinated activated charcoal (IAC) on lung function of patients with moderate chronic obstructive pulmonary disease (COPD) was examined in a double blind randomized placebo controlled parallel group study with 40 patients. In the IAC group, patients showed a statistically significant improvement of FEV1 baseline by 130 ml compared to placebo, corresponding to 8.2% improvement (p = 0.031*). Correlation statistics revealed that the improvement of FEV1 baseline was significantly correlated both to FEV1 post-bronchodilator (p = 0.0020**) and FEV1 post-exercise (0.033*) values. This demonstrates that the improved baseline lung function by IAC did not inhibit a further beta2-adrenoceptor relaxation, and thus that patients did not reach a limit for maximal improvement of the lung function after IAC treatment. Eight patients in the IAC group developed abnormal thyroid hormone levels transiently during the treatment. This side effect was not correlated to improvement of lung function (p = 0.82). No serious adverse effects directly related to the treatment were recorded. In summary, this study demonstrates that iodinated activated charcoal surprisingly and significantly improved lung function of patients with moderate COPD. The underlying mechanism of action is unclear, but is likely to be different from the drugs used today. The immediate conclusion is that further studies are now justified in order to determine clinical efficacy of IAC in COPD and explore possible mechanisms of action.},
  author       = {Skogvall, Staffan and Erjefält, Jonas and Olin, Anders and Ankerst, Jaro and Bjermer, Leif},
  issn         = {1532-3064},
  language     = {eng},
  number       = {6},
  pages        = {905--909},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {Oral iodinated activated charcoal improves lung function in patients with COPD.},
  url          = {http://dx.doi.org/10.1016/j.rmed.2014.03.001},
  volume       = {108},
  year         = {2014},
}